Short-Term Isoflavone Intervention in the Treatment of Severe Vasomotor Symptoms after Surgical Menopause: A Case Report and Literature Review

Table 1

Variables measured at weeks 0 (baseline), 4, and 8.

Variable	Week 0	Week 4	Week 8
Mean number of hot flushes per day^1 [59, 60]	6.00 ± 0.82	4.04 ± 1.00	0.82 ± 1.49
Severity of hot flushes^2 [59, 60]	Moderate	Moderate	Mild
Menopause-specific quality of life questionnaire score^3 [55, 61]
Vasomotor domain	16	15	4
Psychosocial domain	13	15	9
Physical domain	44	51	41
Sexual domain	7	5	3
Total	80	86	57
Serum bone marker
Beta C-telopeptide; β-CTx (ng/mL)	1.28	ND	0.54
Proportion of cell types in vaginal smear
Parabasal cells (%)	100	ND	70.8
Intermediate cells (%)	0	ND	20.4
Superficial cells (%)	0	ND	1.2
Vaginal maturation value (VMV)^4	0	ND	11.4
Hormonal profile
Follicle-stimulating hormone (FSH) (mIU/mL)	118.70	ND	111.30
Luteinizing hormone (LH) (mIU/mL)	87.87	ND	71.77
Estradiol (pg/mL)	<5.00	ND	<5.00
Adherence to isoflavone treatment^5 (%)	ND	91.96%	92.86%

ND: not determined. ¹The number of hot flushes was self-reported by the patient once daily; values represent the average number in a given week. ²The severity of hot flushes was categorized according to the mean number of hot flushes in a given week. ³Higher scores indicate poorer quality of life. ⁴VMV has a range of 0–100, derived from a 300-cell count and calculated using the equation (1 × percentage of superficial cells) + (0.5 × percentage of intermediate cells) + (0 × percentage of parabasal cells).  ⁵Adherence to treatment was determined from consumption of the isoflavone capsules which had been prescribed at the previous visit.